NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers

Reuters

2025/10/06

NeuroSense <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90811) on October 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573772086"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573772086\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573772086?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573772086","market":"nz","top_or_hot":-1,"title":"NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90811) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-06 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90811) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL50KBy6:1","article_id":"2573772086","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573772086","pubTimestamp":1759755657,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers. NeuroSense Therapeutics Ltd.  has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.Disclaimer: This news brief was created by Public Technolog","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NRSN":"Neurosense Therapeutics Ltd"},"translate_title":"NeuroSense Therapeutics宣布PrimeC的积极2b期结果，显示阿尔茨海默病生物标志物显著减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers\n    \n\n        NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90811) on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}